Applicant(s):

Broudy et al.

Serial No.:

09/352,466

Group Art Unit No.:

1644

Filed:

July 13, 1999

Examiner: Not Assigned

For:

Monoclonal Antibodies to Stem Cell Factor Receptors


Docket No.:

A-195CDD

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:



This information disclosure statement is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen, Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Robert B. Winter

Attorney/Agent for Applicant(s) Registration No.: 34,458

Phone: (805) 447-2425

Date: OCTOBER 11, 1897

Please send all future correspondence to: U.S. Patent Operations/ RBW Dept. 430, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1789

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mai

1260